Holen Sie sich die Stockscreener-App
2.11
1.44%
0.03
Opus Genetics Inc Aktie (IRD) Neueste Nachrichten
Opus Genetics (NASDAQ:IRD) Cut to Sell at Wall Street Zen - Defense World
Independent Chairman of Opus Genetics Picks Up 9.5% More Stock - simplywall.st
Caprolactam Chemicals Limited Stock Analysis Technical Signals for YEAR - earlytimes.in
What drives Opus Genetics Inc stock priceEx-Dividend Date Alerts & Small Investment Portfolio - earlytimes.in
Hedge Fund and Insider Trading News: Ken Griffin, Warren Buffett, Bridgewater Associates, AQR Capital Management, Schonfeld Strategic Advisors, D.E. Shaw, Millennium Management, Elliott Management, Discovery Capital Management, Opus Genetics Inc - Insider Monkey
Opus Genetics Advances Gene Therapy for Retinal Degeneration: A Study Update - MSN
Portfolio Shifts: How Opus Genetics Inc stock performs in stagflationWeekly Market Outlook & Low Risk High Reward Trade Ideas - moha.gov.vn
Opus Genetics (NASDAQ:IRD) Director Cam Gallagher Purchases 83,000 Shares - MarketBeat
Shorts Report: Why Opus Genetics Inc R3X1 stock is upgraded to buy - moha.gov.vn
B Riley Securities initiates coverage of Opus Genetics (IRD) with buy recommendation - MSN
Opus Genetics, Inc. (NASDAQ:IRD) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Soaring Eagle Acquisition Corp Equity Warrant Stock Analysis and ForecastLong-Term Growth Stocks & Superior Capital Appreciation - earlytimes.in
Opus Genetics Inc R3X1 Stock Analysis and ForecastMarket Insider Reports & Discover Strategies with Fellow Traders - earlytimes.in
MACD Signals Flash Warning for Compucom Software Limited StockMACD Trading Signals & Minimal Investment Big Returns - earlytimes.in
Opus Genetics rises as eye disease study to proceed without changes - MSN
Rate Hike: Why Opus Genetics Inc stock could benefit from AI revolutionInsider Selling & Proven Capital Preservation Tips - moha.gov.vn
Will Opus Genetics Inc. stock outperform growth indexesProfit Target & Consistent Growth Equity Picks - Улправда
Palmetto Grain Brokerage - Palmetto Grain Brokerage
Will Opus Genetics Inc. stock gain from lower inflationMarket Growth Summary & Low Risk Profit Maximizing Plans - Улправда
Opus Genetics partner files supplemental NDA for presbyopia drug - MSN
Why Opus Genetics Inc. stock is a value investor pick2025 Fundamental Recap & Weekly Breakout Watchlists - Улправда
Opus Genetics Partner Files Supplemental NDA for Presbyopia Drug - TipRanks
Bank Watch: Is Opus Genetics Inc. stock attractive for growth ETFsMarket Volume Summary & Daily Risk Controlled Trade Plans - DonanımHaber
Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Opus Genetics Earnings Notes - Trefis
Opus Genetics (NASDAQ:IRD) Upgraded at Wall Street Zen - MarketBeat
Insider Selling: Opus Genetics (NASDAQ:IRD) Director Sells 4,000,000 Shares of Stock - MarketBeat
Foundation fighting blindness sells $8.6 million in Opus Genetics (IRD) By Investing.com - Investing.com South Africa
Opus Genetics (IRD) Price Target Increased by 13.45% to 7.87 - MSN
Foundation Fighting Blindness Retinal Degeneration Fund Sells 4,000,000 Shares of Opus Genetics Inc (IRD) - GuruFocus
Foundation fighting blindness sells $8.6 million in Opus Genetics (IRD) - Investing.com
Opus Genetics to Present at the J.P. Morgan 2026 Healthcare Conference | Associated Press | syndication news - Enidnews.com
Opus Genetics to Present at the J.P. Morgan 2026 Healthcare Conference - marketscreener.com
Subdued Growth No Barrier To Opus Genetics, Inc. (NASDAQ:IRD) With Shares Advancing 27% - simplywall.st
B. Riley Securities Initiates Coverage of Opus Genetics (IRD) with Buy Recommendation - Nasdaq
B. Riley Initiates Opus Genetics at Buy With $9 Price Target - marketscreener.com
B.Riley initiates Opus Genetics stock with Buy rating on gene therapy potential - Investing.com Canada
Opus Genetics Says Independent Panel Backs Phase 1/2 Trial in Best Disease After Safety Review - marketscreener.com
Opus Genetics rises on update from eye disease study (IRD) - Seeking Alpha
Opus Genetics (IRD) Advances in Clinical Trial for Best Disease Treatment - GuruFocus
Opus Genetics advances Best disease gene therapy trial after positive safety review - Investing.com Canada
Opus Genetics Announces Positive Recommendation from Independent Data Monitoring Committee for Phase 1/2 Trial in Best Disease - The Manila Times
Opus Genetics Announces Positive Recommendation from - GlobeNewswire
Opus Genetics, Inc. (NASDAQ:IRD) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World
Is Opus Genetics Inc. stock positioned well for digital economy2025 Earnings Impact & Daily Market Momentum Tracking - Newser
Opus Genetics, Inc. (NASDAQ:IRD) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
How Opus Genetics Inc. (R3X1) stock trades after rate cutsMarket Risk Analysis & Smart Allocation Stock Reports - Newser
Why Opus Genetics Inc. (R3X1) stock gets analyst attentionOptions Play & High Accuracy Trade Signal Alerts - Newser
Equities Analysts Offer Predictions for Opus Genetics FY2025 Earnings - MarketBeat
How Opus Genetics Inc. (R3X1) stock trades under stagflationAnalyst Downgrade & Fast Entry High Yield Stock Tips - Newser
28.63%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):